Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 2/20 | 0.32 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20297872 | 0.80 | HTR3A (0.40) | ELANEKDM4EMGLLHSD17B10TDP1 | |
| SCHEMBL1067846 | 0.77 | METAP2 (0.46) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5537231 | 0.76 | ELANE (0.61) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL30515124 | 0.76 | ELANE (0.41) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL28623812 | 0.76 | TOP2A (0.50) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28600968 | 0.75 | ELANE (0.59) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL24807093 | 0.73 | ELANE (0.44) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5077318 | 0.73 | ELANE (0.44) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2761642 | 0.73 | ELANE (0.44) | ELANEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5544045 | 0.73 | ELANE (0.44) | ELANEKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | ELANE 1381/4885KDM4E 3110/4885ALDH1A1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.